HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Nicola Santelmo Xavier Ducrocq Jean-Marie Wihlm Gilbert Massard Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mansour, Z. Articles by Massard, G. Search for Related Content PubMed PubMed Citation Articles by Mansour, Z. Articles by Massard, G. Related Collections Lung - cancer Related Article

---

Original Articles: General Thoracic

Persistent N2 Disease After Induction Therapy Does Not Jeopardize Early and Medium Term Outcomes of Pneumonectomy

^a Thoracic Surgery Service, Strasbourg University Hospital, Strasbourg, France
^b Department of Pulmonology, Strasbourg University Hospital, Strasbourg, France

Accepted for publication January 7, 2008.

^_* Address correspondence to Dr Massard, Service de Chirurgie Thoracique, Hôpitaux Universitaires de Strasbourg, 67091 Strasbourg, France (Email: gilbert.massard{at}chru-strasbourg.fr).

Background: Operative management of patients with persistent N2 disease after induction therapy is still debated.

Methods: One hundred fifty-three consecutive patients underwent pneumonectomy from January 1999 until July 2005; 28 patients (18.3%) had persistent N2 disease after induction therapy (group 1), 32 patients (20.9%) had pathologic stage N0 or N1 after induction therapy (group 2), and 93 patients (60.8%) with pathologic N2 disease underwent immediate surgery (group 3). Short-term end points were operative mortality at 30 and 90 days and major complications. Long-term end points were 5-year survival and disease-free survival rates.

Results: Demographics of the three groups were similar (age, sex, side of operation, type of chemotherapy, smoking status, and comorbidity such as coronary artery disease, diabetes, and chronic obstructive pulmonary disease). Thirty-day postoperative mortality was 10.7% in group 1, 3.1% in group 2 (p = 0.257), and 4.3% in group 3 (p = 0.201); 90-day postoperative mortality was 10.7% in group 1, 12.5% in group 2 (p = 0.577), and 9.7% in group 3 (p = 0.558). Incidence of major postoperative complications was similar. Five-year survival rate was 32.2% (median, 28 months; 95% confidence interval, 7 to 43) in group 1, 34.8% (median, 27 months; 95% confidence interval, 7 to 47) in group 2 (p = 0.685), and 12.4% (median, 15 months; 95% confidence interval, 11 to 19) in group 3 (p = 0.127). No statistical difference was found in terms of 5-year event-free survival, or regarding the side of pneumonectomy.

Conclusions: Our results suggest that pneumonectomy is justified in patients with persistent N2 disease after induction chemotherapy.

Related Article

Invited Commentary

Pierre-Emmanuel Falcoz
Ann. Thorac. Surg. 2008 86: 233-234. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				A. W. Kim, L. P. Faber, W. H. Warren, S. Basu, S. C. Wightman, J. A. Weber, P. Bonomi, and M. J. Liptay Pneumonectomy after chemoradiation therapy for non-small cell lung cancer: does "side" really matter? Ann. Thorac. Surg., September 1, 2009; 88(3): 937 - 943. [Abstract] [Full Text] [PDF]

				H. M. Klomp and I. Kappers Is Pneumonectomy Justified in Patients With Locally Advanced NSCLC and Persistent N2 Disease After Induction Chemotherapy? Ann. Thorac. Surg., March 1, 2009; 87(3): 990 - 991. [Full Text] [PDF]

				P.-E. Falcoz Invited Commentary Ann. Thorac. Surg., July 1, 2008; 86(1): 233 - 234. [Full Text] [PDF]